Your browser doesn't support javascript.
loading
Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Treatment-Resistant Depression: A Decade of Clinical Follow-Up.
Hitti, Frederick L; Cristancho, Mario A; Yang, Andrew I; O'Reardon, John P; Bhati, Mahendra T; Baltuch, Gordon H.
Afiliación
  • Hitti FL; Department of Neurosurgery, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Cristancho MA; Corresponding author: Frederick L. Hitti, MD, PhD, University of Pennsylvania, Department of Neurosurgery, 3rd floor Silverstein, 3400 Spruce St, Philadelphia, PA 19104 (Frederick.Hitti@pennmedicine.upenn.edu).
  • Yang AI; Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania.
  • O'Reardon JP; Department of Neurosurgery, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Bhati MT; Department of Psychiatry, Lewis Katz Medical school, Temple University, Philadelphia, Pennsylvania.
  • Baltuch GH; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California.
J Clin Psychiatry ; 82(6)2021 10 19.
Article en En | MEDLINE | ID: mdl-34670026
ABSTRACT

Objective:

Deep brain stimulation (DBS) is an emerging therapy for treatment-resistant depression (TRD) that has shown variable efficacy. This report describes long-term outcomes of DBS for TRD.

Methods:

A consecutive series of 8 patients with TRD were implanted with ventral capsule/ventral striatum (VC/VS) DBS systems as part of the Reclaim clinical trial. Outcomes from 2009 to 2020 were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). Demographic information, MADRS scores, and data on adverse events were collected via retrospective chart review. MADRS scores were integrated over time using an area-under-the-curve technique.

Results:

This cohort of patients had severe TRD-all had failed trials of ECT, and all had failed a minimum of 4 adequate medication trials. Mean ± SD follow-up for patients who continued to receive stimulation was 11.0 ± 0.4 years (7.8 ± 4.3 years for the entire cohort). At last follow-up, mean improvement in MADRS scores was 44.9% ± 42.7%. Response (≥ 50% improvement) and remission (MADRS score ≤ 10) rates at last follow-up were 50% and 25%, respectively. Two patients discontinued stimulation due to lack of efficacy, and another patient committed suicide after stimulation was discontinued due to recurrent mania. The majority of the cohort (63%) continued to receive stimulation through the end of the study.

Conclusions:

While enthusiasm for DBS treatment of TRD has been tempered by recent randomized trials, this small open-label study demonstrates that some patients achieve meaningful and sustained clinical benefit. Further trials are required to determine the optimal stimulation parameters and patient populations for which DBS would be effective. Particular attention to factors including patient selection, integrative outcome measures, and long-term observation is essential for future trial design.Trial Registration ClinicalTrials.gov identifier NCT00837486.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Estimulación Encefálica Profunda / Trastorno Depresivo Mayor / Trastorno Depresivo Resistente al Tratamiento Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Psychiatry Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Estimulación Encefálica Profunda / Trastorno Depresivo Mayor / Trastorno Depresivo Resistente al Tratamiento Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: J Clin Psychiatry Año: 2021 Tipo del documento: Article